Welcome to our dedicated page for Mirum Pharmaceuticals SEC filings (Ticker: MIRM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Mirum Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Mirum Pharmaceuticals's regulatory disclosures and financial reporting.
Mirum Pharmaceuticals is registering 1,500,000 additional shares of common stock under its 2020 Inducement Plan, bringing the plan total to 5,500,000 shares. The additional shares were approved by the Compensation Committee and are the same class as shares previously registered under prior Form S-8 filings. The Registration Statement incorporates by reference specified prior annual, quarterly and current reports filed with the SEC and the companys Form 8-A description of common stock, and states subsequently filed reports under Sections 13, 14 or 15(d) will also be incorporated by reference.
Mirum Pharmaceuticals (MIRM) filed a Form 144 notifying a proposed sale of securities. The filing shows 17,000 common shares to be sold through Morgan Stanley Smith Barney on NASDAQ with an aggregate market value of $1,309,715.70 and total shares outstanding listed as 50,237,647. The securities were acquired and are proposed to be sold on 09/08/2025 via a stock option exercise, with cash payment recorded. The filer reports no securities sold in the past three months for the account. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.
Frazier-affiliated investment vehicles amended a Schedule 13D for Mirum Pharmaceuticals (MIRM) to correct prior attributions and restate holdings. The filing shows Frazier Life Sciences IX, L.P. directly holds 3,566,912 shares (about 7.1% of 50,237,647 outstanding shares as of August 1, 2025). Related Frazier funds and vehicles report additional direct holdings: Frazier Life Sciences X (168,308 shares), Frazier Life Sciences XI (544,954 shares), Frazier Life Sciences Public Fund (1,574,374 shares) and Frazier Life Sciences Public Overage Fund (940,573 shares). Reporting clarifies that certain investment committee members are not attributed beneficial ownership and corrects prior overstatements. Individual reporting persons James N. Topper and Patrick J. Heron are shown with aggregate beneficial ownership positions reflecting the fund holdings and, for Heron, options that affect percentage calculations.
Janus Henderson Group plc reports beneficial ownership of Mirum Pharmaceuticals common stock totaling 5,236,277 shares, representing approximately 10.6% of the outstanding class. The filing shows the reporting entity holds no sole voting or dispositive power and reports shared voting and dispositive power over the stake. A listed subsidiary, JHIUS, is reported as beneficial owner of 5,140,740 shares (about 10.4%) with shared voting and dispositive authority. The filer certifies these securities are held in the ordinary course of business and not to change control of the issuer.
Eric Bjerkholt, Chief Financial Officer of Mirum Pharmaceuticals, sold 8,000 shares on 08/11/2025 at a weighted average price of $65.50 (range $65.31–$66.00) and on 08/12/2025 exercised employee stock options to acquire 2,954 shares at an exercise price of $26.49 per share. After these transactions the filing reports beneficial ownership of 31,190 shares. The filing notes 290 shares were acquired under the company Employee Stock Purchase Plan on May 10, 2025. The related option grant vests with one quarter after January 23, 2024 and the remainder in 36 equal monthly installments, and the form was signed by an attorney-in-fact.
Mirum Pharmaceuticals, Inc. reports that CEO Christopher Peetz exercised 40,000 employee stock options at $2.936 per share on August 11, 2025, receiving 40,000 common shares, and then sold 40,000 shares at $62.00 per share. A footnote notes the reported transaction occurred under a Rule 10b5-1 plan adopted on November 22, 2024, and that the stock option is fully vested with an expiration date of March 11, 2029. Following these transactions, Peetz holds 138,641 common shares directly and 208,570 shares indirectly through The Peetz Family Trust.
Mirum Pharmaceuticals has filed a shelf registration providing a framework to offer common stock, preferred stock, debt securities and warrants, and includes a sales agreement to sell up to $200.0 million of common stock. The company commercializes three approved medicines—Livmarli (maralixibat), Cholbam (cholic acid) and Chenodal/Ctexli (chenodiol)—and markets these products in the U.S. and selected international territories through its specialized commercial team. Mirum has expanded its portfolio via an asset acquisition related to chenodiol and Cholbam and obtained worldwide rights to MRM-3379 through a license agreement to develop a Fragile-X treatment. The prospectus describes ongoing clinical programs for Livmarli and volixibat, regulatory designations for volixibat, and confirms Nasdaq listing under the symbol MIRM. The prospectus highlights inherent business risks and reserves broad discretion over use of proceeds, principally for general corporate purposes.
Mirum Pharmaceuticals, Inc. (MIRM) filed a Form 144 reporting the proposed sale of 40,000 common shares acquired by stock option exercise on 08/11/2025. The sale is to be executed through Morgan Stanley Smith Barney LLC with an aggregate market value of $2,480,000 based on the filing and the company has 50,237,647 shares outstanding as shown.
The filing also records a prior sale during the past three months: Christopher Peetz sold 40,000 shares on 08/07/2025 for $2,210,040. The filer certifies they have no undisclosed material adverse information and notes the securities were paid for in cash at acquisition.
Jolanda Howe, SVP, Global Controller of Mirum Pharmaceuticals (MIRM), reported both non-derivative and derivative transactions affecting her holdings. The filing shows a sale of 10,000 common shares at $58.00, after which her reported direct beneficial ownership stood at 2,426 shares. On the same date she recorded an acquisition-related entry at a $6.27 price for 10,000 common shares, with a reported beneficial ownership figure of 12,426 shares following that transaction.
An employee stock option with a conversion/exercise price of $6.27 covering 10,000 underlying shares is reported and is stated to be fully vested. The filing notes the sale was executed pursuant to a Rule 10b5-1 plan adopted December 16, 2024, and the reporting person is shown as beneficial owner of 40,000 derivative securities following the reported activity.
Mirum Pharmaceuticals CEO Christopher Peetz exercised employee stock options for 40,000 shares of common stock at $2.936 per share on August 7, 2025, then sold 40,000 shares at a weighted average sale price of $55.251022 (range $55.25–$55.485). After these transactions he holds 138,641 shares of common stock directly and 208,570 shares indirectly through The Peetz Family Trust; the stock option is fully vested and expires March 11, 2029.